74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Sandoz Group AG
Closed
59.82
Overview
Share price change
24h
Min
59
Max
60.3
Income | 160M 537M |
|---|---|
Sales | 641M 5.9B |
P/E Sector Avg | 37.747 57.833 |
EPS | 0.87 |
Dividend yield | 1.63 |
Profit margin | 9.093 |
Employees | 22,356 |
EBITDA | 427M 1B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +19.29% upside |
Dividend yield Sector Avg | 1.63% 2.47% |
|---|---|
Next Earnings | 29 Apr 2026 |
Market Cap | -1.8B 27B |
|---|---|
Previous open | 59.82 |
Previous close | 59.82 |
Sandoz Group AG Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Sandoz Group AG Forecast
Price Target
By TipRanks
19.29% upside
12 Months Forecast
Average 71.17 CHF 19.29%
High 80 CHF
Low 62 CHF
Based on 7 Wall Street analysts offering 12 month price targets forSandoz Group AG - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.
Live chat